A new RP-HPLC approach for estimation of potential impurities of Fosamprenavir - method development and validation
- PMID: 40087706
- PMCID: PMC11907861
- DOI: 10.1186/s40360-025-00892-5
A new RP-HPLC approach for estimation of potential impurities of Fosamprenavir - method development and validation
Abstract
The current work aims to develop a reliable and robust RP-HPLC method for analyzing Fosamprenavir and its potential impurities, including isomer, amino, propyl, nitro, and Amprenavir. The method used a Zobrax C18 column with a mobile phase of 0.1% V/V orthophosphoric acid in water and acetonitrile in gradient elution at a flow rate of 1 mL/min to accomplish efficient separation with detection at 264 nm and column temperature of 30 ± 20C. A diluent with a 1:1 water-to-acetonitrile ratio was used to prepare standard and sample solutions. The developed approach was validated as per ICH Q2(R1) guidelines. Fosamprenavir, Amino, Propyl, Isomer, Nitro impurities, and Amprenavir impurities were eluted at retention time (RT) of 5.3 min, 2.3 min, 4.3 min, 4.7 min, 8.1 min and 8.6 min correspondingly with good resolution within a 10-minute run time. Method validation confirmed system suitability, linearity (R² = 0.999), good sensitivity (LOD/LOQ), specificity, precision (% RSD: 0.5-1.7), accuracy (% recovery: 90.9-104.3%), and robustness. The optimized approach excelled existing methods in lower retention time, run time, sensitivity, and linearity for all potential impurities, making it a novel and trustworthy method for monitoring Fosamprenavir drug quality and assessing stated impurities. The established method allows precise measurement of Fosamprenavir and related substances, supporting drug safety and regulatory compliance.
Keywords: Fosamprenavir; Gradient elution; Linearity; Potential impurities; Sensitivity.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
Figures





References
-
- Chapman TM, Plosker GL, Perry CM. Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection. Drugs. 2004;64:2101–24. - PubMed
-
- Crowe SM, Katlama C, Murphy R. Fosamprenavir. Kucers’ The Use of Antibiotics. CRC; 2017. pp. 4104–20.
-
- Torres HA, Arduino RC. Fosamprenavir calcium plus Ritonavir for HIV infection. Expert Rev Anti-infect Ther. 2007;5:349–63. - PubMed
-
- Wire MB, Shelton MJ, Studenberg S. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet. 2006;45(2):137–68. - PubMed
-
- Arvieux C. Amprenavir or Fosamprenavir plus Ritonavir in HIV infection: pharmacology, efficacy and tolerability profile. Drugs. 2005;65:633–59. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources